Roxadustat

Roxadustat, known in development as FG-4592, is a small-molecule, orally active inhibitor of the hypoxia-inducible factor prolyl hydroxylase domain enzymes (HIF-PHDs) and the first-in-class member of the HIF-PHI category ^[1]. Chemically it is an isoquinoline glycinamide derivative that competes with 2-oxoglutarate at the catalytic site of the prolyl hydroxylases, the oxygen-sensing enzymes that normally tag HIF-alpha subunits for destruction. By blocking these enzymes, roxadustat mimics the physiological response to mild hypoxia even under normal oxygen conditions ^[1].

The compound was developed by FibroGen with partners AstraZeneca and Astellas, and it reached market as the first oral therapy in its class, gaining approval in China, Japan, the European Union, and several other regions for anemia associated with chronic kidney disease, in both dialysis and non-dialysis patients ^[2][3]. Its clinical program is among the largest ever assembled for renal anemia, with pivotal Phase 3 studies such as ROCKIES establishing efficacy against established comparators ^[2] and network meta-analyses summarizing the broader HIF-PHI evidence base ^[3][4].

Beyond renal anemia, roxadustat has attracted growing research interest across a range of conditions tied to the HIF pathway, including anemia of inflammation, iron-refractory anemia, chemotherapy-related anemia, tissue and organ injury, and fibrosis ^[1][7]. Preclinical work has explored its effects on renal fibrosis ^[6] and intestinal iron absorption ^[7], while reviewers have also flagged pathway-linked considerations such as vascular calcification that merit monitoring ^[8]. Because HIF stabilizers raise erythropoiesis through the body's native machinery, they are prohibited in competitive sport by the World Anti-Doping Agency; roxadustat is supplied as an oral tablet and remains a prescription medicine rather than a supplement ^[5].

Roxadustat is a hypoxia-inducible factor prolyl-hydroxylase inhibitor used in some countries for anemia of chronic kidney disease; it is not approved for performance or recovery use. It carries documented risks of thrombosis, including vascular access clotting and venous thromboembolism, along with hypertension and, in regulatory review, signals of increased cardiovascular events and mortality in certain groups. Because HIF activation is broadly biologically active, concerns also exist about effects on tumor growth, and off-label use in healthy people is not supported by safety data.

Roxadustat was developed by the American biotechnology company FibroGen as a first-in-class oral inhibitor of the HIF prolyl hydroxylase enzymes, designed to treat anemia by stabilizing the body's own hypoxia-inducible factor signaling. The concept drew directly on the Nobel Prize-winning biology of oxygen sensing, harnessing the same pathway that adapts the body to high altitude to raise endogenous erythropoietin and improve iron handling. FibroGen partnered with AstraZeneca and, in other territories, with Astellas to carry the drug through a large global Phase 3 program in patients with the anemia of chronic kidney disease.

In December 2018 it was approved in China, making it the first drug of an entirely new mechanistic class and a rare instance of a novel therapy launching first in that market. Approvals followed in Japan in 2019 and in the European Union in 2021, though the United States Food and Drug Administration declined to approve it in 2021 over cardiovascular safety questions. Its pivotal trials, including ROCKIES in dialysis patients and OLYMPUS in those not yet on dialysis, established that it could raise hemoglobin without injections.

Roxadustat is regarded as a genuine scientific milestone, translating the biology of oxygen sensing into a convenient oral pill that can rebuild red blood cell mass without the injections that erythropoiesis-stimulating agents require. Its ability to raise the body's own erythropoietin toward levels seen in natural altitude adaptation, rather than producing the sharp supraphysiological spikes of injected agents, is a mechanistically appealing feature.

Because the same pathway improves iron availability and lowers hepcidin, it can help patients whose anemia is complicated by poor iron handling. This same breadth of the HIF program is also the source of its cautions, since the pathway touches blood vessels and metabolism, and cardiovascular and thrombotic risks have been tracked closely, contributing to a mixed regulatory reception across regions. Its capacity to lift oxygen-carrying capacity has additionally made it a compound of keen and controversial interest in endurance sport, where it is prohibited.